AF
VIR icon

Advisornet Financial’s Vir Biotechnology VIR Stock Holding History

Advisornet Financial’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30
Closed -$225 – 2271
2024
Q3 		$225 Hold
30
– – ﹤0.01% 2113
2024
Q2 		$267 Hold
30
– – ﹤0.01% 2003
2024
Q1 		$304 Sell
30
-211
-88% -$2.15K ﹤0.01% 1929
2023
Q4 		$2.42K Buy
241
+2
+0.8% +$18 ﹤0.01% 1661
2023
Q3 		$2.24K Buy
239
+3
+1% +$43 ﹤0.01% 1605
2023
Q2 		$5.79K Buy
236
+6
+3% +$151 ﹤0.01% 1470
2023
Q1 		$5.35K Hold
230
– – ﹤0.01% 1470
2022
Q4 		$5.82K Sell
230
-1,000
-81% -$24.5K ﹤0.01% 1435
2022
Q3 		$24K Hold
1,230
– – ﹤0.01% 1059
2022
Q2 		$31K Hold
1,230
– – ﹤0.01% 1006
2022
Q1 		$32K Hold
1,230
– – ﹤0.01% 1110
2021
Q4 		$52K Sell
1,230
-2,120
-63% -$83.1K ﹤0.01% 1004
2021
Q3 		$146K Buy
3,350
+1,200
+56% +$52K 0.01% 675
2021
Q2 		$102K Buy
+2,150
New +$97.7K 0.01% 783

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Advisornet Financial's VIR Position: Q4 2024 in Review

Advisornet Financial sold out of Vir Biotechnology (VIR) in Q4 2024, closing a stake of 30 shares — an estimated $225 sold.

Advisornet Financial first reported a position in VIR in Q2 2021 and held it in 14 quarters. The position peaked at $146K in Q3 2021. 208 funds tracked by Wall St. Rank hold VIR as of Q4 2024.

  • Advisornet Financial reported no remaining Vir Biotechnology position as of Q4 2024 after selling out during the quarter.
  • Advisornet Financial sold 30 Vir Biotechnology shares in Q4 2024, an estimated $225.
  • Advisornet Financial first reported a position in Vir Biotechnology in Q2 2021 and held it in 14 quarters.
  • Advisornet Financial's Vir Biotechnology position peaked at $146K in Q3 2021.
  • 208 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2024.

Based on Advisornet Financial's 13F filing for Q4 2024, filed 13 Jan 2025.